MOTS-c is usually discussed as a mitochondrial peptide involved in glucose metabolism, insulin sensitivity, exercise adaptation, and cellular stress signaling. A newly finalized 2026 study adds a very different function. Researchers found that MOTS-c behaves like a host defense peptide capable of directly interacting with bacteria, damaging bacterial function, limiting bacterial growth, and changing how monocytes develop into macrophages. The study tested Escherichia coli and methicillin-resistant Staphylococcus aureus, or MRSA, and provides evidence that a peptide encoded by the mitochondrial genome may participate directly in innate immune defense. (Rice et al., 2026, eLife, DOI: 10.7554/eLife.87615.3)
----------------------------------------
Why A Mitochondrial Peptide Would Have Antibacterial Activity
Mitochondria originated from ancient bacteria that entered into a symbiotic relationship with ancestral eukaryotic cells. Modern mitochondria still retain several bacterial characteristics, including their own circular DNA, specialized ribosomes, and portions of their own genetic machinery. MOTS-c is a 16-amino-acid peptide associated with a short open reading frame within mitochondrial 12S rRNA. It was initially identified as a mitochondrial-derived signaling peptide involved in metabolic homeostasis and insulin sensitivity. (Lee et al., 2015, PMID: 25738459)
The new immune findings fit with this evolutionary background. Organisms across biology produce short peptides that function as host defense peptides, also called antimicrobial peptides. These peptides frequently carry positive electrical charges and contain hydrophobic regions that allow them to interact with negatively charged bacterial membranes. MOTS-c has both characteristics.
The researchers identified a hydrophobic core containing the sequence YIFY and a positively charged C-terminal region containing RKLR. At physiological pH, MOTS-c carries a net positive charge of approximately +3. This combination allows the peptide to interact with bacterial surfaces through both electrostatic and hydrophobic forces. (Rice et al., 2026, DOI: 10.7554/eLife.87615.3)
That makes MOTS-c different from a peptide that only changes immune signaling indirectly. The study provides evidence that MOTS-c can physically interact with bacteria itself.
----------------------------------------
MOTS-c Directly Attached To Bacteria
Researchers exposed E. coli to MOTS-c and observed rapid physical interaction between the peptide and bacterial cells. MOTS-c disappeared from the surrounding solution while appearing in bacterial cell lysates, indicating that the peptide was associating directly with the bacteria.
MOTS-c also caused rapid aggregation of E. coli and MRSA. Instead of remaining freely dispersed, bacteria clustered together after exposure to the peptide. Bacterial aggregation is a known function of several host defense peptides because immobilizing bacteria can limit their movement and potentially make them easier for immune cells to clear.
The effect depended on the chemical structure of MOTS-c. When researchers replaced either its hydrophobic YIFY region or positively charged RKLR region with alanine residues, much of the antibacterial activity disappeared. Increasing the salt concentration also disrupted the effect because higher ionic strength interferes with the electrostatic interactions used by positively charged host defense peptides to bind bacterial surfaces. (Rice et al., 2026, DOI: 10.7554/eLife.87615.3)
These experiments strengthen the argument that MOTS-c was not simply producing a nonspecific toxic effect. Specific structural features of the peptide were required for the antibacterial activity.
----------------------------------------
What MOTS-c Did To The Bacterial Membrane
Electron microscopy showed progressive changes in bacterial membrane structure after MOTS-c exposure. Bacterial membranes are critical for maintaining ion gradients, generating energy, transporting nutrients, and controlling what enters and exits the organism. Disrupting the membrane can therefore interfere with several essential bacterial functions at once.
MOTS-c treatment reduced ATP concentrations inside E. coli. Real-time metabolic testing also showed disturbances in both bacterial respiration and glycolysis. These findings are consistent with membrane dysfunction interfering with the bacterial cell's ability to maintain energy production.
Bacterial growth subsequently slowed in a concentration-dependent manner. Repeated intermediate exposures also produced substantial growth inhibition, showing that both concentration and exposure pattern affected the antibacterial response.
This mechanism differs from many conventional antibiotics. Antibiotics may inhibit bacterial ribosomes, cell-wall synthesis, DNA replication, folate metabolism, or other specific pathways. Host defense peptides frequently attack physical properties of the bacterial membrane while also producing additional intracellular effects.
That does not mean MOTS-c is automatically capable of replacing antibiotics or overcoming antibiotic resistance. The study demonstrates antibacterial activity under experimental conditions. Pharmacokinetics, achievable tissue concentrations, stability, toxicity, bacterial resistance, and efficacy in actual human infections remain unanswered.
----------------------------------------
The MRSA Experiment
MRSA is particularly relevant because it is resistant to multiple commonly used antibiotics and is capable of causing severe skin, soft-tissue, bloodstream, and systemic infections.
In the new study, researchers exposed MRSA to 100 micromolar MOTS-c and then introduced the bacteria into mice using an acute peritonitis model. Mice receiving untreated MRSA had only 16.7 percent survival during the observation period. Mice receiving MRSA that had first been exposed to MOTS-c had 100 percent survival.
The MOTS-c-treated MRSA preparation also showed a 3.4-fold reduction in colony-forming units before administration. (Rice et al., 2026, DOI: 10.7554/eLife.87615.3)
The design of this experiment matters. MOTS-c was mixed directly with the bacteria before the bacteria were introduced into the animals. This experiment therefore demonstrates that MOTS-c can substantially reduce MRSA infectivity, but it is not the same as giving MOTS-c systemically after an established infection and showing that the animal recovers.
A related experiment using a different bacterial concentration produced a 19.8-fold reduction in recoverable MRSA colonies after MOTS-c treatment.
The magnitude of these effects is substantial for preclinical research, but the model should not be described as evidence that MOTS-c cures MRSA infections in humans.
----------------------------------------
An Older Study Already Found Something Similar
The antibacterial connection did not appear for the first time in 2026. A 2017 Molecular Immunology study tested MOTS-c in mice challenged with MRSA and found substantial improvements in survival and bacterial clearance. (Zhai et al., 2017, PMID: 29096170)
In one experiment, pretreatment with MOTS-c increased survival in MRSA-infected mice from approximately 20 percent to 78.75 percent. In another experiment designed to more closely resemble treatment after infection, MOTS-c was administered two hours after the MRSA challenge. Survival increased from approximately 50 percent in controls to 100 percent in the higher-dose treatment group.
The doses used in those experiments were extremely large by human peptide standards, including 20 mg/kg and 50 mg/kg in mice. Those values describe an animal experiment and have no established relationship to appropriate human administration.
MOTS-c also reduced bacterial burden in several tissues and improved the ability of macrophages to kill bacteria.
The 2017 study therefore supports an antibacterial function through a somewhat different experimental design than the new eLife paper. The new study goes much further in determining why MOTS-c might have this effect and identifies the peptide as a potential mitochondrial-encoded host defense peptide.
----------------------------------------
MOTS-c Also Changed Macrophage Function
The new study found two different antibacterial mechanisms occurring at the same time. MOTS-c could interact directly with bacteria, and MOTS-c could also change immune-cell behavior.
Macrophages are immune cells responsible for recognizing, engulfing, processing, and destroying pathogens. They also coordinate inflammatory signaling and communicate with other components of the immune system.
Researchers exposed monocytes to MOTS-c while those cells were differentiating into macrophages. MOTS-c altered the developmental program of these cells and produced macrophages with different gene-expression and metabolic characteristics.
MOTS-c-programmed macrophages demonstrated greater bacterial clearance when exposed to E. coli.
This means MOTS-c did not simply behave like an external antimicrobial chemical. It appeared capable of modifying the immune cells responsible for bacterial defense as well. (Rice et al., 2026, DOI: 10.7554/eLife.87615.3)
----------------------------------------
The Human Monocyte Findings
Parts of the study used primary human monocytes rather than only mouse cells.
Endogenous MOTS-c increased as primary human monocytes differentiated toward macrophages. The researchers also found that treating primary human monocytes with MOTS-c altered their differentiation response.
Experiments using THP-1 human monocyte cells showed that bacterial lipopolysaccharide, or LPS, increased endogenous MOTS-c. Interferon gamma also increased MOTS-c expression.
The immune system encounters bacterial-associated signaling, interferon and bacterial signals increase endogenous MOTS-c, MOTS-c can directly attack bacteria, and MOTS-c also helps influence the differentiation and function of cells responsible for bacterial clearance.
That combination is one reason the researchers classified MOTS-c as an interferon-linked mitochondrial host defense peptide.
The limitation is that much of the deeper mechanistic work used THP-1 cells, an immortalized human monocytic cell line. Additional confirmation in primary human immune cells is still needed.
----------------------------------------
MOTS-c Reprogrammed Hundreds Of Immune-Related Genes
MOTS-c was previously shown to enter the nucleus during cellular stress and influence nuclear gene expression. That work demonstrated that a peptide encoded by mitochondrial DNA could communicate directly with the nuclear genome. (Kim et al., 2018, PMID: 29983246)
The immune study found a similar process during monocyte differentiation. Endogenous MOTS-c moved into the nucleus as monocytes differentiated, while externally administered MOTS-c also entered monocytes and demonstrated strong nuclear localization.
RNA sequencing found that MOTS-c significantly changed the expression of 945 genes during early monocyte differentiation.
Several affected pathways were related to immune function, interferon signaling, antigen processing, antigen presentation, cellular metabolism, and macrophage differentiation.
This makes the immune effect of MOTS-c broader than membrane disruption alone. The same molecule can potentially interact directly with a bacterium and also enter mammalian immune cells and influence transcription.
----------------------------------------
MOTS-c Did Not Simply Increase Inflammation
Fighting an infection requires inflammatory signaling, but uncontrolled inflammation can become destructive. Severe bacterial infection and sepsis can produce excessive cytokine signaling that damages organs even while the immune system is attempting to eliminate the pathogen.
The 2017 MRSA study found that MOTS-c reduced inflammatory cytokines including TNF-alpha, IL-6, and IL-1 beta while increasing the anti-inflammatory cytokine IL-10. MOTS-c also altered MAPK signaling and increased AhR and STAT3-associated signaling in macrophages. (Zhai et al., 2017, PMID: 29096170)
At the same time, macrophage bacterial killing improved.
This distinction matters because reducing inflammation does not necessarily mean suppressing immune defense. An ideal antimicrobial immune response clears the pathogen while preventing inflammatory signaling from continuing beyond what is required.
The newer study again showed changes in inflammatory signaling after macrophages had been programmed with MOTS-c. Their cytokine response to LPS differed from untreated macrophages rather than simply becoming globally more inflammatory.
MOTS-c is therefore better described as immunomodulatory than as a general immune stimulant.
----------------------------------------
How Macrophages Killed More Bacteria
The 2017 study provides additional detail about the macrophage mechanism. MOTS-c increased macrophage phagocytosis and enhanced bacterial killing. Researchers observed increased expression of dectin-1 along with changes in nitric oxide and reactive oxygen species production.
Phagocytosis allows a macrophage to engulf a bacterium into an intracellular compartment. Reactive oxygen species, nitric oxide, acidic environments, enzymes, and other antimicrobial systems can then help destroy the captured organism.
The newer paper complements those findings by suggesting that MOTS-c can influence macrophage development before the infection even occurs.
Instead of only stimulating an already mature macrophage, MOTS-c exposure during differentiation produced macrophages with a different transcriptional and metabolic program that demonstrated improved bacterial clearance.
This creates a possible two-stage model. MOTS-c can directly interfere with bacteria while simultaneously influencing the immune cells responsible for clearing the remaining organisms.
----------------------------------------
Why The Mitochondrial Origin Matters
The immune system is traditionally described as being encoded by genes in the nuclear genome. The MOTS-c findings suggest that mitochondrial DNA may also encode molecules that participate directly in host defense.
That possibility fits with mitochondrial evolution. Mitochondria originated from bacteria, and modern bacteria use short peptides to compete with other microorganisms. Some of these bacterial peptides function as bacteriocins capable of inhibiting competing bacterial species.
MOTS-c may represent a remnant or adaptation of this ancient biology.
The researchers propose that mitochondria and the nuclear genome may have co-evolved immune signaling systems after the original bacterial ancestor of the mitochondrion became incorporated into the ancestral eukaryotic cell.
That remains an evolutionary hypothesis rather than something experimentally proven by the current study. The experimental finding is that a mitochondrial-encoded peptide has chemical and functional properties consistent with a host defense peptide.
----------------------------------------
This Is Different From Calling MOTS-c An Antibiotic
The current evidence does not establish MOTS-c as an antibiotic treatment.
The direct antibacterial experiments generally used micromolar peptide concentrations under controlled laboratory conditions. Peptide concentrations at the surface of bacteria in an experimental tube do not automatically translate to concentrations achievable in human blood or infected tissue.
Peptides can also be degraded rapidly by proteases, bind plasma proteins, distribute differently between tissues, or fail to reach an infected compartment at sufficient concentrations.
The new mouse experiment involved bacteria being exposed directly to MOTS-c before administration. The older 2017 study provides stronger evidence for an effect after infection because MOTS-c was administered to the animals following the MRSA challenge, but those experiments still involved mice and very high experimental doses.
No controlled human infection trial currently shows that MOTS-c treats MRSA, E. coli infection, sepsis, or another bacterial disease.
----------------------------------------
Does MOTS-c Improve Immune Health?
That wording goes beyond what the study establishes.
Human immunity includes neutrophils, macrophages, monocytes, dendritic cells, T cells, B cells, antibodies, complement, natural killer cells, epithelial barriers, cytokines, interferons, and many additional systems.
The current research shows specific effects involving bacterial interaction, monocyte differentiation, macrophage bacterial clearance, interferon-associated signaling, and inflammatory regulation.
It does not show that people administering MOTS-c get fewer infections, recover faster from illness, produce stronger vaccine responses, improve antibody production, or have broadly superior immune function.
The more accurate claim is that MOTS-c appears to have previously unrecognized antimicrobial and immunomodulatory functions.
----------------------------------------
Why The MRSA Finding Matters
Antibiotic resistance is one reason host defense peptides receive significant research attention. MRSA has acquired resistance to beta-lactam antibiotics and can accumulate resistance to additional antimicrobial drugs.
Many host defense peptides attack bacterial membranes through electrostatic and hydrophobic interactions rather than depending on one bacterial enzyme or receptor. That creates a mechanism distinct from many traditional antibiotics.
MOTS-c required both its hydrophobic and positively charged structural regions for antibacterial activity. Removing either region substantially reduced its effect. This makes the antibacterial mechanism chemically understandable rather than being based only on an observed reduction in bacterial growth.
It remains unknown how rapidly bacteria could develop resistance to MOTS-c, whether physiologically achievable concentrations would kill human pathogens, or whether MOTS-c would work synergistically with existing antibiotics.
----------------------------------------
What The Evidence Supports
Strong preclinical evidence now supports direct antibacterial activity of MOTS-c against E. coli and MRSA. The 2026 study demonstrated bacterial binding, aggregation, membrane disruption, impaired bacterial energy metabolism, reduced growth, and loss of antibacterial activity when important structural portions of MOTS-c were altered. The mechanistic evidence is substantially stronger than simply observing improved survival in an animal infection model. (Rice et al., 2026, DOI: 10.7554/eLife.87615.3)
Moderate preclinical evidence supports MOTS-c as an immunomodulator of monocytes and macrophages. Human monocyte models show endogenous MOTS-c responding to inflammatory and differentiation signals, while MOTS-c exposure altered macrophage development, nuclear gene expression, cytokine responses, and bacterial clearance. Much of this work still relies on THP-1 cells rather than primary human immune cells.
Strong animal evidence supports protective effects in MRSA infection models. The 2017 study demonstrated reduced bacterial burden, improved macrophage function, altered inflammatory signaling, and markedly improved survival in infected mice. The 2026 study independently demonstrated that MOTS-c-treated MRSA lost much of its infectivity in a mouse peritonitis model. (Zhai et al., 2017, PMID: 29096170; Rice et al., 2026, DOI: 10.7554/eLife.87615.3)
Human clinical evidence for treating infection is currently absent. No controlled human trial has demonstrated that externally administered MOTS-c prevents or treats bacterial infections, MRSA, sepsis, or impaired immune function.
----------------------------------------
Why This Study Changes The MOTS-c Conversation
MOTS-c was originally identified because of its effects on metabolic homeostasis and insulin sensitivity. It was later shown to enter the nucleus during cellular stress and regulate nuclear gene expression. Exercise research subsequently connected endogenous MOTS-c with skeletal muscle and stress adaptation. The immune literature now adds another biological role. (Lee et al., 2015, PMID: 25738459; Kim et al., 2018, PMID: 29983246)
MOTS-c may function as a mitochondrial stress signal, metabolic regulator, nuclear signaling peptide, and host defense peptide rather than fitting into one narrow category.
The immune findings are particularly notable because MOTS-c appears to work on both sides of an infection. It can interact directly with bacteria while also influencing the mammalian immune cells responsible for eliminating bacteria.
The strongest conclusion is not that MOTS-c is a new human antibiotic. The stronger conclusion is that mitochondria may encode part of our innate antimicrobial defense system, and MOTS-c appears to be one of the first peptides demonstrating that connection experimentally.
A peptide originally studied for metabolism can physically associate with bacteria, damage bacterial function, reduce MRSA infectivity, respond to interferon signaling, enter immune-cell nuclei, alter hundreds of genes during macrophage development, and improve bacterial clearance in experimental models.
The next step is determining whether any of those effects translate into clinically useful concentrations and outcomes in humans.
----------------------------------------
References
Rice MC, Imun M, Jung SW, Park CY, Kim JS, Lai RW, Barr CR, Son JM, Tor K, Kim E, Lu RJ, Cohen I, Benayoun BA, Lee C. MOTS-c is a mitochondrial-encoded interferon-linked host defense peptide. eLife. Version of Record published August 18, 2026. DOI: 10.7554/eLife.87615.3. PMID not yet assigned at the time of this breakdown.
Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459.
Zhai D, Ye Z, Jiang Y, et al. MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA. Mol Immunol. 2017;92:151-160. PMID: 29096170.
Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28(3):516-524.e7. PMID: 29983246.
Disclaimer: As always nothing in my breakdowns is meant to be medical or legal advice and is purely educational
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.